RSS

Motif Bio

Motif Bio has received an award from the Cystic Fibrosis Foundation, which will fund important in vitro testing to advance the development of iclaprim for the treatment of lung infections in patients with cystic fibrosis more

News

Motif Bio’s investigational drug candidate, iclaprim, has been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis. more

News

The Food and Drug Administration (FDA) has granted fast track designation for Motif Bio’ iclaprim intravenous (IV) drug to treat acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP) more

News